{
    "ticker": "SCPH",
    "name": "ScPharmaceuticals Inc.",
    "description": "ScPharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with serious conditions, particularly in the field of heart failure and other cardiovascular diseases. Founded in 2017, ScPharmaceuticals aims to enhance the treatment landscape by providing novel formulations that enable the administration of therapies in a more efficient and patient-friendly manner. The company is best known for its lead product, Furoscix, a subcutaneous formulation of furosemide, which is designed to be administered outside of the hospital setting. This groundbreaking approach allows patients to receive treatment in the comfort of their own homes, potentially improving adherence and quality of life. ScPharmaceuticals is committed to addressing unmet medical needs and advancing patient-centric care, and it is actively engaged in clinical trials to further develop its product pipeline. With a team of experienced professionals in drug development, clinical research, and commercialization, ScPharmaceuticals is dedicated to making a significant impact in the biopharmaceutical industry and improving outcomes for patients suffering from debilitating conditions.",
    "industry": [
        "Biopharmaceutical",
        "Healthcare"
    ],
    "headquarters": "Framingham, Massachusetts, USA",
    "founded": "2017",
    "website": "https://www.scpharmaceuticals.com",
    "ceo": "John Tucker",
    "social_media": {
        "twitter": "https://twitter.com/scpharma",
        "linkedin": "https://www.linkedin.com/company/scpharmaceuticals"
    },
    "investor_relations": "https://investors.scpharmaceuticals.com",
    "key_executives": [
        {
            "name": "John Tucker",
            "position": "CEO"
        },
        {
            "name": "David K. R. Sweeney",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Pharmaceuticals",
            "products": [
                "Furoscix"
            ]
        }
    ],
    "seo": {
        "meta_title": "ScPharmaceuticals Inc. | Innovative Biopharmaceuticals for Heart Failure",
        "meta_description": "Explore ScPharmaceuticals Inc., a leader in developing innovative therapies for heart failure and serious cardiovascular diseases. Learn about their patient-centric solutions.",
        "keywords": [
            "ScPharmaceuticals",
            "Biopharmaceuticals",
            "Heart Failure",
            "Furoscix",
            "Cardiovascular Diseases"
        ]
    },
    "faq": [
        {
            "question": "What is ScPharmaceuticals known for?",
            "answer": "ScPharmaceuticals is known for developing innovative therapies for heart failure, particularly its subcutaneous formulation of furosemide, Furoscix."
        },
        {
            "question": "Who is the CEO of ScPharmaceuticals?",
            "answer": "John Tucker is the CEO of ScPharmaceuticals Inc."
        },
        {
            "question": "Where is ScPharmaceuticals headquartered?",
            "answer": "ScPharmaceuticals is headquartered in Framingham, Massachusetts, USA."
        },
        {
            "question": "What is Furoscix?",
            "answer": "Furoscix is a subcutaneous formulation of furosemide designed to be administered in a home setting for patients with heart failure."
        },
        {
            "question": "When was ScPharmaceuticals founded?",
            "answer": "ScPharmaceuticals was founded in 2017."
        }
    ],
    "competitors": [
        "AMGN",
        "VRTX",
        "ALNY",
        "REGN"
    ],
    "related_stocks": [
        "PFE",
        "MRK",
        "JNJ",
        "ABBV"
    ]
}